Download
slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Title of Abstract Goes Here – Please Make Sure Study Number is Listed in Title PowerPoint Presentation
Download Presentation
Title of Abstract Goes Here – Please Make Sure Study Number is Listed in Title

Title of Abstract Goes Here – Please Make Sure Study Number is Listed in Title

94 Vues Download Presentation
Télécharger la présentation

Title of Abstract Goes Here – Please Make Sure Study Number is Listed in Title

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Title of Abstract Goes Here – Please Make Sure Study Number is Listed in Title Author’s Names Author’s Affiliations Poster development instructions: Be sure to check the poster specifications for each meeting as these often vary from meeting to meeting. You should know the poster size prior to starting to layout your poster. The components included in this template are not necessarily required (such as “Abstract”) and those not required can be deleted. Size: 42 x 42 OBJECTIVES RESULTS • Bullet Number One – sample text sample text sample text sample text sample sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text. • Bullet Number Two – sample text sample text sample text sample text sample sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text. PATIENTS Table IV. Patient Accrual sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 Table VII. Overall sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 • Bullet Number One – sample text. • Bullet Number Two – sample text sample text. SAFETY AND TOXICITY ABSTRACT ELIGIBILITY Table I. Patient Accrual sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 Table V. Pretreatment sample text sample text sample text 100 Sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 • Bullet Number One – sample text sample text sample text sample text sample sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text. • Bullet Number Two – sample text sample text sample text sample text sample sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text. • Bullet Number Three – sample text sample text sample text sample text sample sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text Background: Patients with tumors Patients with tumors Patients with tumors Patients with tumors Patients with tumors Patients with tumors Patients with tumors Patients with tumors Patients with tumors Patients with tumors. Be sure to check the poster specifications for each meeting as these often vary from meeting to meeting. You should know the poster size prior to starting to layout your poster. The components included in this template are not necessarily required and those not required can Methods:Patients with tumors Patients with tumors Patients with tumors Patients with tumors Patients with tumors Patients with tumors Patients with tumors Patients with tumors Patients with tumors Patients with tumors. Results:106 patients were enrolled 106 patients were enrolled 106 patients were enrolled 106 patients were enrolled 106 patients were enrolled 106 patients were enrolled 106 patients were enrolled 106 Conclusion:Both regimens were well tolerated with acceptable Both regimens were well tolerated with acceptable Both regimens were well tolerated with acceptable tolerated with acceptable Both regimens were Table VIII. Causes of Death sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 Table II. Pretreatment sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 CONCLUSIONS • Sample text Sample text Sample text Sample text Sample text Sample text Sample text Sample text Sample text Sample text • Sample text Sample text Sample text Sample text Sample text • Sample text Sample text Sample text Sample text Sample text • Sample text Sample text Sample text Sample text Sample text STUDY DESIGN Study design goes here. BACKGROUND EFFICACY Figure 1: Treatment Schema Table III. Pathologic Response sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 • Bullet Number One – sample text sample text sample text sample text sample sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text text sample text. • Bullet Number Two – sample text sample text sample text sample text sample sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text text sample text. • Bullet Number Three – sample text sample text sample text sample text sample sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text text sample text. Table VI. Toxicities sample text sample text sample text 100 sample text sample text sample text 100 sample text sample text sample text 100 Aim 1 Number One – sample text sample text sample text sample text sample sample text sample text Number Two – sample text sample text sample text sample text sample sample text sample text. Aim 2 Number One – sample text sample text sample text sample text sample sample text sample text Number Two – sample text sample text sample text sample text sample sample text sample text. REFERENCES • Sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text. • Sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text • Sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text • Sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text • Sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text • Sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text • Sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text • Sample text sample text sample text sample text sample text sample text sample text sample text sample text sample text Sponsor acknowledgements NCT number